Skip to main navigation Skip to search Skip to main content

Corrigendum to "The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII" [Mol Genet Metab 2020 Mar;129(3):219-227]

  • Raymond Y. Wang
  • , José Francisco da Silva Franco
  • , Jaime López-Valdez
  • , Esmeralda Martins
  • , Vernon Reid Sutton
  • , Chester B. Whitley
  • , Lin Zhang
  • , Tricia Cimms
  • , Deborah Marsden
  • , Agnieszka Jurecka
  • , Paul Harmatz

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

We would like to correct the clinicaltrials.gov study registration number mentioned in the manuscript in several areas: In the abstract, the NCT number mentioned and linked (NCT02377921) is incorrect. The sentence that reads “… completed a Phase 3, randomized, placebo-controlled, blind-start, single crossover study (UX003-CL301; NCT02377921) …” should instead read, “… completed a Phase 3, randomized, placebo-controlled, blind-start, single crossover study (UX003-CL301; NCT02230566) … The link to the corrected NCT number should point to: https://clinicaltrials.gov/ct2/show/NCT02230566 The authors would like to apologize for any inconvenience caused. DOI of original article: doi: https://doi.org/10.1016/j.ymgme.2020.01.003

Original languageEnglish (US)
Pages (from-to)285
Number of pages1
JournalMolecular Genetics and Metabolism
Volume131
Issue number1-2
DOIs
StatePublished - Sep 1 2020

Bibliographical note

Publisher Copyright:
© 2020 The Author(s)

Fingerprint

Dive into the research topics of 'Corrigendum to "The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII" [Mol Genet Metab 2020 Mar;129(3):219-227]'. Together they form a unique fingerprint.

Cite this